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Chemoradiotherapy (CRT) is accepted as the standard initial treatment for squamous cell anal cancer. However, frail elderly patients
cannot always tolerate full-dose CRT. This paper reports the results of a modified regimen for this group of patients. In all, 16 patients
with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use
of full-dose CRT were included in this protocol. The median age was 81 (range 77–91). Patients received a dose of 30Gy to the
gross tumour volume plus 3cm margin in all directions. Concurrent chemotherapy comprised 5-fluorouracil 600mgm
 2 given over
24h on days 1–4 of radiotherapy. The treatment was well tolerated. All 16 patients completed treatment as planned. Only one
patient experienced any grade 3 toxicity (skin). The local control at a median follow-up of 16 months was 73% (13 out of 16). The
overall survival was 69% and disease-specific survival 86%. This is a well-tolerated regimen for elderly/poor performance patients with
anal cancer, which can achieve high rates of local control and survival. Longer follow-up will determine whether these encouraging
results are maintained.
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Anal cancer is rare. Within the Yorkshire Cancer Network, with a
population of 2.6 million, on average 30–40 patients with anal
cancer are registered each year (Yorkshire Cancer Registry Report,
1996).
Chemoradiotherapy (CRT) is accepted as the standard initial
treatment for squamous anal cancer with surgery used as salvage
treatment for recurrent or persistent disease. Norman Nigro was
the first to describe in a case report complete response in three
patients treated with mitomycin C (MMC) and 5-fluorouracil
(5-FU) combined with 30Gy radiotherapy (Nigro et al, 1974). A
subsequent report described the outcome for 45 patients treated
with the same regimen with a complete response rate of 84% on
biopsy 6 weeks after completion of treatment (Leichman et al,
1985).
A number of investigators reported encouraging results of initial
nonsurgical treatment either using radiotherapy alone (Cummings
et al, 1982; Eschwege et al, 1985; Papillon and Montbarbon, 1987;
Martenson and Gunderson, 1993) or concurrent CRT (Flam et al,
1987; Cummings et al, 1991; John et al, 1996). This in turn led to
three pivotal randomised control trials that investigated the role of
CRT. The UKCCCR and the EORTC trials compared CRT with
radiotherapy alone, whereas the RTOG trial compared CRT using
5-FU with and without the addition of MMC (Flam et al, 1996;
UKCCCR, 1996; Bartelink et al, 1997). These results have led to
CRT (using a total dose of radiation of at least 50Gy combined
with 5-FU and MMC) being established as the primary treatment
of anal cancer.
In routine clinical practice, however, clinicians face the problem
of deciding the best treatment option for elderly patients who are
frail, suffer from significant medical co-morbid conditions or who
are for other reasons considered unfit to undergo standard (full-
dose) chemoradiation. In view of the impressive results obtained
by Nigro and colleagues in 45 patients using a total dose of
radiation of 30Gy, we designed an institutional protocol taking
into account the needs of this patient group and evaluated the
toxicity and outcome using a total dose of 30Gy of radiation
delivered using an involved field approach with reduced dose
concurrent 5-FU. The aim of this paper is to present the results of
this protocol.
PATIENTS AND METHODS
Patient characteristics
Between January 2000 and December 2003, 101 patients with
squamous cell carcinoma of the anal canal or margin were treated
with CRT. In all, 15 of these patients were aged 75 or over but fit
enough to be treated with standard dose CRT. However, 16
patients were deemed not suitable to be treated with our standard
CRT protocol due to their age, performance status or co-
morbidity. It is these patients who form the basis of this
retrospective study. Six (37%) of the patients were males. All 16
patients had biopsy-proven squamous cell carcinoma situated in
the anal canal (six patients), anal margin (six patients) or both
(four patients). Patients were referred to a single consultant
clinical oncologist (DSM) at Leeds Cancer Centre, Cookridge
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sHospital from the surrounding hospitals within the Yorkshire
Cancer Network.
All patients were initially considered for standard dose CRT.
However, in all patients there was a combination of factors, either
significant co-morbidity (as outlined in Table 1), combined with
their age, and/or performance status that in the opinion of the
treating clinical oncologist meant the patient would not tolerate, or
complete standard dose CRT without major treatment modifica-
tion. Seven patients were of World Health Organisation (WHO)
performance status (PS) 1, eight patients PS 2 and one patient PS 3.
Patients were all treated according to an institutional protocol, as
outlined below.
A pretreatment examination, including the anal margin, canal
and inguino-femoral region was performed in all patients. Female
patients routinely underwent vaginal examination as part of the
initial assessment. The tumour site was defined as canal or margin
dependent on the location of the majority of the disease. A full
blood count and biochemical profile were also obtained in all
patients. Of the 16 patients, 13 had metastatic disease excluded by
CT scanning of the abdomen and pelvis and chest X-ray. Three
patients did not undergo radiological assessment as they had
tumours where the risk of metastatic disease was thought to be
low, and in addition there were no symptoms or signs to suggest
regional or metastatic spread. Patient and tumour characteristics
are shown in Table 1. The median age was 81 years (range 77–91).
Radiotherapy
Treatment was delivered as a single phase without a boost or
planned gap. All patients were simulated and treated prone with a
full bladder. Gross tumour volume (GTV) was defined as all visible
macroscopic tumour and any nodal disease considered clinically
or radiologically to be significant. In the perianal and inguinal
area, this was marked with radio-opaque markers at the time of
simulation. Moulded wax block bolus to the perianal skin was used
during the treatment. Patients were planned using an orthogonal
film or virtual simulation technique. Small bowel and rectal
contrast were used routinely.
The radiotherapy fields were defined as the GTV plus a margin
of 3cm in all directions. For anal margin cancers with no extension
into the anal canal, a direct field was used (five patients, median
field dimensions 10 10). Seven patients without nodal disease
were treated using either a three- or four-field planned technique
(median field dimensions 17 14 15cm
3) and four patients were
treated with parallel opposed fields (median field dimensions
14 16cm
2). Bolus was also applied to involved groin nodes.
Photons were used for all patients. The dose prescription was 30Gy
in 15 fractions as an applied dose in the case of a direct field or the
same dose prescribed to the ICRU intersection point for multiple
field arrangements.
Chemotherapy
Concurrent chemotherapy comprised 5-FU 600mgm
 2 in 1litre N
saline infused via a peripheral cannula over 24h on days 1–4 of
the first week of treatment. As part of the protocol, all patients
were given prophylactic antibiotics (oral Ciprofloxacin 250mg
twice daily) at the commencement of treatment and continued
until any areas of moist desquamation following CRT had healed.
This is also standard policy in the current National Cancer
Research Network ACT 2 phase III trial.
Patients were seen weekly during their radiotherapy to assess
toxicity including a full blood count. Following completion of
treatment, patients continued to be seen on a weekly basis until
any toxicity had resolved.
Follow-up
All patients were followed up jointly by the referring surgeon and
oncologist. Patients were seen 3 monthly for the first 2 years and
then 6 monthly until 5 years. At each visit a careful history and
examination was performed, including assessment of the anal
canal and margin and inguinal regions. Investigations (including
radiological assessment) were only performed if the patient’s
symptoms or findings on examination suggested relapse.
Statistical methods
Local failure was defined as recurrent or persistent disease more
than 3 months following completion of CRT. Complete response
was determined clinically and biopsy confirmation was not
routinely obtained. Disease-free survival and overall survival were
estimated using the method of Kaplan–Meier.
RESULTS
Treatment compliance and acute toxicity
All 16 patients completed CRT to the planned radiotherapy dose of
30Gy in 15 fractions with 5-FU given concurrently in the first
week. The calculated median GFR was 35mlmin
 1 (range 18–54)
(Cockcroft and Gault, 1976). Two patients were hospitalised
throughout their treatment for social reasons. One patient required
admission for symptom control part way through their radio-
therapy. The remaining patients were all treated as outpatients
apart from the initial 4 days of chemotherapy.
Although all patients experienced some degree of skin toxicity in
the majority, this was mild erythema. Only one patient experienced
grade 3 skin toxicity (Common Toxicity Criteria Version 2) and
this patient required hospitalisation. One patient reported
diarrhoea, which was mild and controlled by medication. No
patients experienced haematological toxicity of any grade for the
4 weeks during treatment. One patient required a stoma prior to
commencing treatment because of a recto-vaginal fistula. This has
not been reversed. No patients have required stomas following
Table 1 Pretreatment characteristics, radiotherapy details
Age Stage Pre-morbidity Radiotherapy details
1 77 T2N0 Previous hysterectomy
Hypertension
P
2 78 T3N0 Severe learning difficulties S
3 91 T2N0 Aortic valve disease
Heart failure
S
4 83 T2N0 Recent fracture of neck of femur P
5 82 T2N0 IHD S
6 78 T2N0 NIDDM
Hypertension
P
7 85 T4N2 Previous breast cancer PO
8 88 T3N3 Performance status 3 PO
9 78 T3N0 IHD P
10 80 T2N0 Metastatic prostate cancer P
11 79 T2N0 IHD PO
12 82 T2N0 IHD
Vascular disease
S
13 81 T2N0 NIDDM
Hypertension
Vascular disease
P
14 83 T3N0 Emphysema P
15 89 T2N0 Hypertension
Asthma
PO
16 81 T3N0 Previous CVA S
P¼planned three-field technique; S¼single direct field; PO¼parallel opposed
technique; IHD¼ischaemic heart disease; NIDDM¼non-insulin-dependent dia-
betes; CVA¼cardiovascular accident.
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patient for the management of post-treatment toxicity.
Local control and survival
The median follow-up is 16 months for all patients (range 2–45
months) and 17 months (range 5–45) for surviving patients. The
disease status is given in Table 2. Three (19%) patients have failed
locally, one with persistent disease and two with a local recurrence
at 9 and 14 months. The actuarial local control rate is 73%
(Figure 1). None of these patients were considered fit enough to
undergo salvage surgery. Two of the patients who failed locally
presented with locally advanced T3 tumours.
Three patients have died during follow-up, two from their anal
cancer (one patient with local recurrence and the patient with
persistent disease) and one from intercurrent illness (there was no
evidence of recurrent tumour at the time of death). One patient is
alive with local recurrence. The overall survival is 69% (Figure 2A)
and the disease-specific survival 86% (Figure 2B).
DISCUSSION
Chemoradiotherapy is the accepted primary treatment for
squamous cell anal cancer, while abdominal perineal excision is
reserved for persistent or confirmed locally recurrent disease. Two
large randomised controlled trials have confirmed the superiority
of CRT over radiotherapy alone in terms of both local control and
colostomy-free survival (Flam et al, 1996; UKCCCR, 1996;
Bartelink et al, 1997). A third trial demonstrated that a
combination of 5-FU and MMC was shown to be superior to 5-
FU alone when combined with radiation. In all of these studies the
primary tumour and lymph nodes were treated with doses of 45Gy
with an additional boost dose of 5.4–25Gy in selected patients.
However, patients included in all three of these protocols were of a
good PS and had a median age of approximately 60. The results
reported in this paper are of a protocol specifically designed for a
group of elderly and/or poorer PS patients with anal cancer who
experience significant symptoms from their disease and can expect
a reasonable survival but would not be able to tolerate full-dose
CRT.
There have been several reports of the use of low-dose
radiotherapy combined with chemotherapy to treat anal cancer.
In Nigro’s paper of 21 patients treated with 30Gy in 15 fractions
combined with MMC and 5-FU followed by surgery, 57% of
patients had significant downstaging or no tumour at the time of
Table 2 Patient outcome
Patient Local disease status Status
1 ND (15 months) A (15 months)
2 ND (10 months) A (10 months)
3 LR (9 months) A (17 months)
4 ND (12 months) A (12 months)
5 ND (16 months) A (16 months)
6 ND (22 months) A (22 months)
7 ND (5 months) A (5 months)
8 ND (13 months) A (13 months)
9 ND (18 months) A (18 months)
10 ND (5 months) A (5 months)
11 ND (36 months) A (36 months)
12 ND (37 months) A (37 months)
13 ND (1 month) D (2 months)
14 LR (14 months) D (19 months)
15 ND (45 Months) A (45 months)
16 PD (3 months) D (11 months)
ND¼no disease; LR¼local relapse; PD¼persistent disease; A¼alive; D¼dead.
Times in brackets are the times of recurrence or death or times of last follow-up.
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Figure 1 Local control.
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Figure 2 (A) Overall survival. (B) Disease-specific survival.
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ssurgery (Buroker et al, 1977). A subsequent report of 45 patients
treated with the same regimen led to 84% having complete
response and 89% remaining disease-free at a median follow-up of
50 months (Leichman et al, 1985). Smith et al treated 42 patients
with the same regimen. In total, 90% of patients with T1 and T2
tumours were free of disease at 33 months, while only 38% of
patients with T3 or T4 tumours achieved disease control (Smith
et al, 1994). Low-dose radiochemotherapy has also been shown to
be both effective and tolerable in HIV-infected patients with anal
cancer (Peddada et al, 1997).
To date, there has been only one study which has specifically
investigated the role of CRT in elderly patients with anal cancer.
Valentini et al (1997) used CRT to treat a group of 17 patients with
anorectal carcinoma who were all over the age of 75. Of note,
patients with a poor PS or significant co-morbidity were excluded.
Of these 17, seven patients had anal cancer and were treated with
split course radiotherapy (24Gy, 1.8Gy per fraction repeated after
a break of 4–5 weeks) combined with 5-FU and MMC in the first
week of each treatment course. The treated volume included the
tumour plus inguinal and pelvic nodes. Treatment was well
tolerated, with only one patient developing grade 3 RTOG skin
toxicity. Four of the seven patients with anal cancer achieved a
complete response and the sphincter was preserved in six patients.
The protocol used in our patients was developed from the phase
II studies reported by Nigros group and our own experience
of using a total of 30Gy to microscopic disease and a boost dose
of 20Gy to macroscopic disease without a planned gap in
our standard regimen (Melcher and Sebag-Montefiore, 2003).
To date we have not seen any isolated failures in the low-dose
region. To our knowledge, our study is the first to report
the results of a protocol of low-dose radiotherapy combined
with chemotherapy specifically designed for use in elderly patients
and/or poor performance patients. Although the results should
be interpreted with some caution as the follow-up is still
short, initial results suggest that this modified regimen can
not only achieve good symptom control but also has a high
chance of local control. Longer follow-up of this group of elderly
patients will determine whether the local control of 73%, similar to
that seen in our patients treated with high-dose radiotherapy, is
maintained.
Our protocol was well tolerated by this group of elderly frail
patients. All patients completed their CRT as planned with
minimum toxicity and only one grade 3 skin toxicity. No patients
required admission for haematological or gastrointestinal toxicity.
As expected, the greatest treatment-related morbidity was skin
toxicity, but in all patients this was easily managed with
appropriate skin care and simple analgesics.
Of the patients treated, three have developed local recurrence. Of
these three, two had large T3 tumours at presentation. Other
groups have reported similar findings of reduced local control for
patients with more advanced tumours (Cummings et al, 1991;
Melcher and Sebag-Montefiore, 2003). For these patients there are
a number of possible ways to improve our regimen without
increasing the dose of radiotherapy. The dose of 5-FU could be
increased, although this should be done with caution. A second
method of intensifying the regimen would be to add MMC if renal
function is adequate. Of note, only a small proportion of our
patients would have had adequate enough renal function to receive
MMC. Furthermore, a significant risk of haematological toxicity
can be anticipated in patients receiving 5-FU and MMC compared
to patients receiving 5-FU alone (Flam et al, 1996). Finally, by
substituting the 5-FU for an oral fluoropyrimidine, the regimen
could be made totally out-patient based and therefore more
convenient for patients and radiotherapy departments. This
approach is under consideration for fluoropyrimidine-based CRT
in rectal cancer and would equally apply to anal cancer (Crane and
Sargeant, 2004).
CONCLUSION
With an aging population, the number of cases of anal cancer in
elderly frail patients is likely to increase. Many of these patients are
not able to tolerate full-dose CRT, but are expected to survive long
enough to require treatment. Treatment with single or short
hypofractionated regimens might undertreat these patients,
resulting in patients dying with painful, uncontrolled local disease.
The availability of a low-toxicity, relatively uncomplicated regimen
means that more patients can be offered treatment, which not only
improves symptoms but also offers the prospect of long-term
tumour control.
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